Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.660
-0.030 (-1.78%)
Nov 21, 2024, 4:00 PM EST - Market closed
Protalix BioTherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 45.67 | 65.49 | 47.64 | 38.35 | 62.9 | 54.69 | Upgrade
|
| Revenue Growth (YoY) | -28.22% | 37.48% | 24.22% | -39.03% | 15.00% | 59.73% | Upgrade
|
| Cost of Revenue | 29.29 | 22.98 | 19.59 | 16.35 | 10.87 | 10.9 | Upgrade
|
| Gross Profit | 16.38 | 42.51 | 28.05 | 22 | 52.03 | 43.8 | Upgrade
|
| Selling, General & Admin | 13.34 | 14.96 | 11.71 | 12.73 | 11.15 | 9.9 | Upgrade
|
| Research & Development | 11.95 | 17.09 | 29.35 | 29.73 | 38.17 | 44.62 | Upgrade
|
| Operating Expenses | 25.29 | 32.05 | 41.06 | 42.46 | 49.32 | 54.52 | Upgrade
|
| Operating Income | -8.91 | 10.46 | -13.01 | -20.46 | 2.71 | -10.72 | Upgrade
|
| Interest Expense | -1.83 | -3.18 | -2.53 | -7.52 | -9.67 | -7.34 | Upgrade
|
| Interest & Investment Income | 1.29 | 1.29 | 1.15 | 0.4 | 0.44 | 0.41 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.14 | - | - | - | - | -0.63 | Upgrade
|
| EBT Excluding Unusual Items | -9.59 | 8.57 | -14.4 | -27.58 | -6.52 | -18.28 | Upgrade
|
| Pretax Income | -9.59 | 8.57 | -14.4 | -27.58 | -6.52 | -18.28 | Upgrade
|
| Income Tax Expense | 0.02 | 0.25 | 0.53 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -9.61 | 8.31 | -14.93 | -27.58 | -6.52 | -18.28 | Upgrade
|
| Net Income | -9.61 | 8.31 | -14.93 | -27.58 | -6.52 | -18.28 | Upgrade
|
| Net Income to Common | -9.61 | 8.31 | -14.93 | -27.58 | -6.52 | -18.28 | Upgrade
|
| Shares Outstanding (Basic) | 73 | 68 | 48 | 44 | 29 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 73 | 82 | 48 | 44 | 29 | 15 | Upgrade
|
| Shares Change (YoY) | -0.59% | 70.04% | 9.81% | 51.43% | 96.44% | 0.85% | Upgrade
|
| EPS (Basic) | -0.13 | 0.12 | -0.31 | -0.62 | -0.22 | -1.23 | Upgrade
|
| EPS (Diluted) | -0.13 | 0.09 | -0.31 | -0.62 | -0.22 | -1.23 | Upgrade
|
| Free Cash Flow | 7.17 | -2.47 | -25.63 | -11.74 | -26.76 | -19.99 | Upgrade
|
| Free Cash Flow Per Share | 0.10 | -0.03 | -0.53 | -0.27 | -0.92 | -1.35 | Upgrade
|
| Gross Margin | 35.86% | 64.91% | 58.87% | 57.37% | 82.71% | 80.08% | Upgrade
|
| Operating Margin | -19.50% | 15.97% | -27.32% | -53.36% | 4.31% | -19.59% | Upgrade
|
| Profit Margin | -21.03% | 12.69% | -31.33% | -71.92% | -10.37% | -33.42% | Upgrade
|
| Free Cash Flow Margin | 15.70% | -3.77% | -53.80% | -30.62% | -42.55% | -36.54% | Upgrade
|
| EBITDA | -7.62 | 11.65 | -11.93 | -19.34 | 4.01 | -9.1 | Upgrade
|
| EBITDA Margin | -16.69% | 17.79% | -25.04% | -50.44% | 6.38% | -16.64% | Upgrade
|
| D&A For EBITDA | 1.28 | 1.19 | 1.09 | 1.12 | 1.3 | 1.62 | Upgrade
|
| EBIT | -8.91 | 10.46 | -13.01 | -20.46 | 2.71 | -10.72 | Upgrade
|
| EBIT Margin | -19.50% | 15.97% | -27.32% | -53.36% | 4.31% | -19.59% | Upgrade
|
| Effective Tax Rate | - | 2.97% | - | - | - | - | Upgrade
|
| Revenue as Reported | 45.67 | 65.49 | 47.64 | 38.35 | 62.9 | 54.69 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.